eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2022
vol. 73
 
Share:
Share:
more
 
 
abstract:
Original paper

Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma

Jaudah Al-Maghrabi
1, 2
,
Zuhoor Al-Mansouri
2
,
Abdullah Al-Harbi
3
,
Mourad Assidi
4, 5
,
Abdelbaset Buhmeida
4, 5
,
Wafaey Gomaa
6

1.
Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia
2.
Department of Pathology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
3.
Department of Pathology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
4.
Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
5.
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
6.
Department of Pathology, Faculty of Medicine, Minia University, Al Minia, Egypt
Pol J Pathol 2022; 74 (1): 14-20
Online publish date: 2022/06/28
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Glypicans (GPC) are involved in the developmental morphogenesis and regulatory processes of cell signalling. Abnormal expression has been observed in different cancer types.

One hundred and thirty-seven colorectal carcinoma (CRC) and 44 nodal metastases were used to create tissue microarrays. Immunohistochemistry was done to detect and evaluate the impact of immunostaining patterns of GPC-3 protein in CRC.

GPC-3 immunostaining is increased in CRC and nodal metastasis (p < 0.001) and was not association with clinicopathological parameters. GPC-3 immunostaining was associated with longer disease-free survival (p = 0.021) and overall survival (p = 0.05).

For the first time, we show GPC-3 immunostaining association with survival outcomes in CRC. GPC-3 may be used as an independent prognostic factor for survival in CRC.
keywords:

glypican-3, colorectal carcinoma, immunostaining, survival

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.